News | May 26, 2025
Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
These observations are procedural in nature and none of them are related to data integrity
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
The Subsidiary has received one inspectional observation in Form 483
Subscribe To Our Newsletter & Stay Updated
